Abstract: According to one embodiment, a lightning device includes a base member, a light source on the base member, a light guide body configured to guide at least part of light forwardly emitted from the light source. The light guide body includes an incident portion covering the front of at least the part of the light source, a bent light guide portion outwardly bent from the incident portion and configured to curvedly guide incident main light to the outside, and a light-emitting surface located on the distal end of the bent light guide portion, directly exposed to the outside of the device, and configured to emit the curvedly guided light laterally or rearwardly relative to the light source.

Abstract: A compound of formula [I-W]: wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

Abstract: A photoelectric conversion module is disclosed. The photoelectric conversion module includes a photoelectric conversion panel and a moisture barrier plate. The photoelectric conversion panel includes first and second surfaces, a photoelectric converter between the first and second surfaces, and a conductive lead. An opening is located on the first surface. The moisture barrier plate is located on the second surface and includes first and second principal surfaces, and a through-hole extending from the first principal surface to the second principal surface. The moisture barrier plate covers the one principal surface. The through-hole does not overlap the opening. A filling member is located in a gap between the first surface and the first principal surface. The conductive lead goes through a part of the filling member, and has an end electrically coupled to the photoelectric converter and the other end coming out through the opening to the exterior.

Abstract: The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

Abstract: According to one embodiment, a lighting device includes a radiation surface, at least one light source provided to face the radiation surface, and an optical control member provided between the radiation surface and the light source and includes optical characteristics of transmission, diffraction, diffusion, and reflection, which vary for regions in the optical control member, a distribution of each of the optical characteristics being determined by positions relative to the at least one light source. The optical control member is formed in a sheet shape which is controlled by at least one of a reflective film having a reflection factor distribution, and a reflective film having a numerical aperture distribution, and lenses.

Abstract: According to one embodiment, a lighting device includes a light source, and a semi-transmissive reflection layer opposing the light source. The semi-transmissive reflection layer includes a pattern including transmitting portions or reflecting portions. The pattern includes a pattern formed of the transmitting portions each having a hole conformation in a region to which a high volume of light form the light source incident, and a pattern formed of the reflection portions each having a dot conformation in a region to which a low volume of light form the light source incident.

Abstract: A compound of formula [I-W]: wherein each symbol is as defined in the description, or a pharmaceutically acceptable salt thereof.

Abstract: The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

Abstract: A tandem pulse arc welding control apparatus includes a voltage detector; a voltage setting unit; a pulse-peak-current-reference-value setting circuit; a pulse-base-current-reference-value setting circuit; an error amplifier that calculates a pulse-peak-current variation value and a pulse-base-current variation value; an adder that calculates a pulse-peak-current value; an adder that calculates a pulse-base-current value; a pulse-waveform selection circuit that outputs the pulse-peak-current value in a pulse peak period, and that outputs the pulse-base-current value in a pulse base period; and an output control circuit that controls a current value for a second welding wire. Because an appropriate welding voltage can be obtained with this configuration, a high welding quality can be realized.

Abstract: A display apparatus according to the present invention has a plurality of electroconductive layers outside of an image display area. Mutually adjacent ones of the electroconductive layers are electrically connected by a resistor. The resistor has a first region, and a second region which is more separated from the image display area than the first region. The area of the second region per unit length in the direction separating from the image display area is smaller than the area of the first region.

Abstract: According to one embodiment, an lighting apparatus includes a base member, a light source configured to emit visible light, and a translucent cover including a translucent region which covers at least a front surface of the light source and emits the light emitted from the light source to the outside. The light source is provided on a front surface flat section of the base member, a luminous intensity of the light emitted from the light source has a directionality which is strong in a normal direction of the front surface flat section and becomes zero on a rear surface side. The translucent cover includes a domed shape having a maximum diameter at a position higher than a height of the position where the light source is arranged, and a transmittance of a region opposing the light source is 60% or less.

Abstract: The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

Abstract: According to one embodiment, a planar lighting device includes a plurality of light sources, a light guide layer provided on a light-emission side of the light sources and configured to guide light from the light sources, and a reflective layer provided on an opposite side of the light guide layer to the light sources and through which a part of the light is transmitted. The light guide layer includes light-scattering properties for scattering light and is formed so that optical transmittance T based on the light-scattering properties is 40%?T?93%.

Abstract: A display apparatus according to the present invention has a plurality of electroconductive layers outside of an image display area. Mutually adjacent ones of the electroconductive layers are electrically connected by a resistor. The resistor has a first region, and a second region which is more separated from the image display area than the first region. The area of the second region per unit length in the direction separating from the image display area is smaller than the area of the first region.

Abstract: The present invention relates to a compound represented by the following formula [I] wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof and an anti-HCV agent and an HCV polymerase inhibitor containing this compound. The compound of the present invention shows an anti-HCV activity based on the HCV polymerase inhibitory activity, and useful as an agent for the prophylaxis or treatment of hepatitis C.

Abstract: A display apparatus according to the present invention has a plurality of electroconductive layers outside of an image display area. Mutually adjacent ones of the electroconductive layers are electrically connected by a resistor. The resistor has a first region, and a second region which is more separated from the image display area than the first region. The area of the second region per unit length in the direction separating from the image display area is smaller than the area of the first region.

Abstract: The present invention provides a triazolopyridine compound having a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability. The present invention relates to a compound represented by the following formula [I]: wherein each symbol is as defined in the specification, or a pharmaceutically acceptable salt thereof, or a solvate thereof, as well as a prolyl hydroxylase inhibitor or erythropoietin production-inducing agent containing the compound. The compound of the present invention shows a prolyl hydroxylase inhibitory action and an erythropoietin production-inducing ability and is useful as a prophylactic or therapeutic agent for various diseases and pathologies (disorders) caused by decreased production of erythropoietin.

Abstract: An illuminant substrate includes a substrate, first and second light emitting members provided on the substrate, a first anode covering the first light emitting member, a second anode covering the second light emitting member, a resistor located between the first and second light emitting members and electrically connecting the first and second anodes, and a rib laminated on the resistor. A side face of the resistor facing the first light emitting member projects toward the first light emitting member further than a side face of the rib facing the first light emitting member, and a side face of the resistor facing the second light emitting member projects toward the second light emitting member further than a side face of the rib facing the second light emitting member.

Abstract: A flat panel type display apparatus, which includes: a front substrate having a plurality of phosphor layers, an anode covering at least the plurality of phosphor layers, an electrode for applying a voltage to the anode, and a resistor member connecting the anode to the electrode; and a rear substrate having a plurality of electron-emitting devices corresponding to the plurality of phosphor layers, is characterized by including an insulating layer, and in that the insulating layer overlaps with the resistor member in an area, and isolates the anode formed in the area from the resistor member.